Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Eli Lilly’s new top dealmaker discusses how the company has changed its M&A approach now that it is the most valuable pharmaceutical company in the world. The piece is primarily a strategic interview about capital allocation and acquisition criteria rather than a discrete transaction or earnings update. No specific deal size, approval, or financial guidance was disclosed.

Analysis

Eli Lilly’s new top dealmaker discusses how the company has changed its M&A approach now that it is the most valuable pharmaceutical company in the world. The piece is primarily a strategic interview about capital allocation and acquisition criteria rather than a discrete transaction or earnings update. No specific deal size, approval, or financial guidance was disclosed.